Reviews/Alcohol and Health/Alcohol raises breast cancer risk
Cancer · ALC-CA-02 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
Across the studies gathered here, women who drink more alcohol tend to develop breast cancer more often, and the risk rises as intake rises. The pattern holds in several separate long-term studies that followed large groups of women over many years, and in one pooled analysis that combined the primary data of more than a million women [13][17][10][16]. The effect is small for light drinking and larger for heavy or lifetime-heavy drinking, and it appears for both main biological subtypes of the disease. None of these are randomised experiments, so some of the risk could in principle be explained by other habits that travel with drinking, and one study of cancers diagnosed before age 50 found no alcohol effect [20]. The panel weighed the breadth and consistency of the evidence against these limits in reaching its view.
Five large prospective cohorts and one pooled analysis of the primary data of 1,089,273 women report a positive, dose-dependent association between alcohol intake and breast cancer [13][17][10][16][23]. The pooled analysis gives relative risks of 1.35 (1.23-1.48) for ER+ and 1.28 (1.10-1.49) for ER- disease comparing >=30 g/day with 0 g/day [13]; EPIC reports a 4.2% risk increase per 10 g/day across 11,576 cases [17]; the Sister Study reports HR 1.35 (1.15-1.58) for >=230 versus <60 drinks/year [16]; and a US cohort analysis finds RR 1.13 (1.06-1.20) at 5-14.9 g/day, driven by breast cancer [10]. A decomposition cohort reports a total excess risk ratio of 1.55 for alcohol with a significant direct effect (ERR 0.44, p=0.003) [23]. Risk-factor models treat alcohol as a modifiable contributor to breast cancer risk [7][12]. The contested point: The evidence divides on whether the association is uniform and causal: the corpus is entirely observational, and the early-onset analysis [20] found no alcohol association for breast cancer diagnosed before age 50, where only physical activity was significant. The point estimates at light intake are small (RR 1.02-1.13 [10]), a range the Sceptic argues residual confounding could plausibly produce for the lightest-drinking strata.
All 23 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Alcohol and Health, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
All on-claim evidence is observational; no RCT tests alcohol on breast cancer incidence, so residual confounding from correlated diet, HRT, SES and physical activity cannot be excluded.
A directly relevant primary cohort [20] reports alcohol showed no association for early-onset (<50) breast cancer, indicating the effect is not uniform across all populations/age strata.
Where it remains uncertain. All evidence is observational so confounding cannot be excluded, and one early-onset analysis found no alcohol association for breast cancer before age 50 [20].
Aleatory
At light intake the relative risks are close to 1.0 (RR 1.02-1.13 [10]), so individual-level risk at low consumption is only modestly raised.
Epistemic
The only randomised study [3] is a 20-person crossover that did not produce a significant estradiol increase, leaving the proposed hormonal pathway undemonstrated in this corpus.
Inferential
No randomised trial tests alcohol on breast cancer incidence; the association rests on cohorts where correlated diet, hormone therapy, socioeconomic status and physical activity could contribute.
The load-bearing papers from a corpus of 23, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Risk-stratification model treating alcohol as an established modifiable BC risk factor.
“For women in the highest decile of risk owing to nonmodifiable factors, those who had low BMI, did not drink or smoke, and did not use MHT had risks comparable to an average woman in the general population.”
Panel auditInternal validity: high · scope of inference: Combined risk stratification for US white women; not an isolated alcohol effect.Key limitations: alcohol not isolated · US white women only · model development, not etiologic estimate
US cohorts showing elevated risk even at light-to-moderate intake, driven by breast cancer.
“for women, even an alcohol consumption of 5-14.9 g/day was associated with increased risk of alcohol related cancer (relative risk 1.13 (95% confidence interval 1.06 to 1.20)), driven by breast cancer.”
Panel auditInternal validity: high · scope of inference: US female health professionals, light-to-moderate drinking; the significant female excess is in alcohol-related cancers driven by breast cancer.Key limitations: effect reported for composite alcohol-related cancers (breast-driven), not breast-only RR · self-reported intake · health-professional sample
Pooled analysis of primary data from 20 cohorts (1,089,273 women) establishing a positive dose association across ER subtypes.
“Alcohol consumption was positively associated with risk of ER+ and ER- breast cancer. The pooled multivariable RRs (95% confidence intervals) comparing ≥ 30 g/d with 0 g/day of alcohol consumption were 1.35 (1.23-1.48) for ER+ and 1.28 (1.10-1.49) for ER- breast cancer”
Panel auditInternal validity: high · scope of inference: Breast cancer risk by ER status across pooled international cohorts; directly the claim's relationship.Key limitations: observational, residual confounding · self-reported intake
It measures hormone changes, not breast cancer risk; the primary estradiol change was not statistically significant and other hormone changes carry CIs spanning zero.
Panel auditInternal validity: medium · scope of inference: Short-term hormonal effects of one daily wine in ER+ breast cancer survivors on aromatase inhibitors; an intermediate marker, not cancer risk.Key limitations: n=20, wide CIs · mechanistic surrogate not incidence · survivors on AI, not general risk
4 of 23 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Breadth, independence, dose-response and cross-subtype consistency of primary cohort evidence carry the claim to Established, held just below the top of the band by its uniformly observational design and the early-onset null.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Causal confirmation beyond observational design. Every on-claim study is observational, so the association cannot be separated from correlated diet, hormone therapy, socioeconomic status and physical activity. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A Mendelian randomisation study using alcohol-metabolism genetic variants, or a randomised reduction trial on biomarker endpoints, to probe causality where an incidence RCT is infeasible.
Open question: Is the alcohol-breast cancer association causal, or partly driven by confounders that travel with drinking? Why it is still open: The corpus is entirely observational and no study in it isolates alcohol from correlated diet, HRT, SES and physical activity.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19